Pharmacokinetics of quinacrine efflux from mouse brain via the P-glycoprotein efflux transporter

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Ahn, Misol ^a,b   Ghaemmaghami, Sina ^a,b   Huang, Yong ^a   Phuan, Puay Wah ^a   May, Barnaby C H ^a,b,c   Giles, Kurt ^a,b   DeArmond, Stephen J ^a,b   Prusiner, Stanley B ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Mesynthes Ltd   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DISULFIRAM; GLYCOPROTEIN P; MEPACRINE; QUINIDINE; VERAPAMIL; ANTINEOPLASTIC AGENT; CYCLOSPORIN; ENZYME INHIBITOR; MULTIDRUG RESISTANCE PROTEIN; NERVE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG TRANSPORT; ENZYME INHIBITION; FEMALE; MALE; MOUSE; NONHUMAN; STEADY STATE; TOXICITY TESTING; WILD TYPE; ANIMAL; BRAIN; DRUG ANTAGONISM; GENETICS; METABOLISM; MOUSE MUTANT;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN; CYCLOSPORINE; ENZYME INHIBITORS; FEMALE; MALE; MICE; MICE, MUTANT STRAINS; NERVE TISSUE PROTEINS; P-GLYCOPROTEIN; QUINACRINE;

EID: 84863607136     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039112     Document Type: Article

References (29)

1. Doh-ura K, Iwaki T, Caughey B, (2000) Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol 74: 4894-4897.
2. Korth C, May BCH, Cohen FE, Prusiner SB, (2001) Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 98: 9836-9841.
3. Collins SJ, Lewis V, Brazier M, Hill AF, Fletcher A, et al. (2002) Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol 52: 503-506.
4. Benito-Leon J, (2004) Combined quinacrine and chlorpromazine therapy in fatal familial insomnia. Clin Neuropharmacol 27: 201-203.
5. Doh-ura K, Ishikawa K, Murakami-Kubo I, Sasaki K, Mohri S, et al. (2004) Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol 78: 4999-5006.
6. Gayrard V, Picard-Hagen N, Viguie C, Laroute V, Andreoletti O, et al. (2005) A possible pharmacological explanation for quinacrine failure to treat prion diseases: pharmacokinetic investigations in a ovine model of scrapie. Br J Pharmacol 144: 386-393.
7. Goodman LS, Gilman A, editors (1975) The pharmacological basis of therapeutics. 5th ed. New York: Macmillan.
8. Wallace DJ, (1989) The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. Semin Arthritis Rheum 18: 282-296.
9. Zipper J, Kessel E, (2003) Quinacrine sterilization: a retrospective. Int J Gynaecol Obstet 83: S7-S11.
10. Berman JD, Lee LS, (1983) Activity of oral drugs against Leishmania tropica in human macrophages in vitro. Am J Trop Med Hyg 32: 947-951.
11. Connelly MC, Kierszenbaum F, (1984) Modulation of macrophage interaction with Trypanosoma cruzi by phospholipase A2-sensitive components of the parasite membrane. Biochem Biophys Res Commun 121: 931-939.
12. Neznanov N, Gorbachev AV, Neznanova L, Komarov AP, Gurova KV, et al. (2009) Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications. Cell Cycle 8: 3960-3970.
13. Gao JT, Liu SH, Yan YE, Wu Y, Wu HT, et al. (2009) Quinacrine protects neuronal cells against heat-induced injury. Cell Biol Int 33: 874-881.
14. Geng Y, Kohli L, Klocke BJ, Roth KA, (2010) Chloroquine-induced autophagic vacuole accumulation and cell death in glioma cells is p53 independent. Neuro Oncol 12: 473-481.
15. Wang W, Ho WC, Dicker DT, MacKinnon C, Winkler JD, et al. (2005) Acridine derivatives activate p53 and induce tumor cell death through Bax. Cancer Biol Ther 4: 893-898.
16. Dohgu S, Yamauchi A, Takata F, Sawada Y, Higuchi S, et al. (2004) Uptake and efflux of quinacrine, a candidate for the treatment of prion diseases, at the blood-brain barrier. Cell Mol Neurobiol 24: 205-217.
17. Nakajima M, Yamada T, Kusuhara T, Furukawa H, Takahashi M, et al. (2004) Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 17: 158-163.
18. Huang Y, Okochi H, May BC, Legname G, Prusiner SB, et al. (2006) Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4/5 and its brain accumulation is limited by P-glycoprotein. Drug Metab Dispos 34: 1136-1144.
19. Jonker JW, Wagenaar E, van Deemter L, Gottschlich R, Bender HM, et al. (1999) Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug. Br J Pharmacol 127: 43-50.
20. Fromm MF, (2004) Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 25: 423-429.
21. Schinkel AH, Wagenaar E, Mol CA, van Deemter L, (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97: 2517-2524.
22. Pardridge WM, (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2: 3-14.
23. Ghaemmaghami S, Ahn M, Lessard P, Giles K, Legname G, et al. (2009) Continuous quinacrine treatment results in the formation of drug-resistant prions. PLoS Pathog 5: e1000673.
24. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, et al. (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491-502.
25. Spilman P, Lessard P, Sattavat M, Bush C, Tousseyn T, et al. (2008) A gamma-secretase inhibitor and quinacrine reduce prions and prevent dendritic degeneration in murine brains. Proc Natl Acad Sci USA 105: 10595-10600.
26. Yung L, Huang Y, Lessard P, Legname G, Lin ET, et al. (2004) Pharmacokinetics of quinacrine in the treatment of prion disease. BMC Infect Dis 4: 53-59.
27. Gorbachev AV, Gasparian AV, Gurova KV, Gudkov AV, Fairchild RL, (2007) Quinacrine inhibits the epidermal dendritic cell migration initiating T cell-mediated skin inflammation. Eur J Immunol 37: 2257-2267.
28. Guo C, Gasparian AV, Zhuang Z, Bosykh DA, Komar AA, et al. (2009) 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways. Oncogene 28: 1151-1161.
29. Dolphin GT, Chierici S, Ouberai M, Dumy P, Garcia J, (2008) A multimeric quinacrine conjugate as a potential inhibitor of Alzheimer's beta-amyloid fibril formation. Chembiochem 9: 952-963.